FDAnews
www.fdanews.com/articles/96399-hydra-lands-potential-195m-deal-with-pfizer-on-pain-drugs

Hydra Lands Potential $195M Deal With Pfizer on Pain Drugs

July 27, 2007

Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million.
BioWorld Online